Amylyx Pharmaceuticals, Inc./$AMLX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Employees
123
Headquarters
Website
AMLX Metrics
BasicAdvanced
$1.5B
-
-$1.77
-0.33
-
Price and volume
Market cap
$1.5B
Beta
-0.33
52-week high
$16.96
52-week low
$2.60
Average daily volume
1.3M
Financial strength
Current ratio
13.702
Quick ratio
13.347
Long term debt to equity
1.492
Total debt to equity
1.788
Profitability
EBITDA (TTM)
-192.966
Gross margin (TTM)
13,947.07%
Net profit margin (TTM)
22,448.42%
Operating margin (TTM)
29,104.21%
Effective tax rate (TTM)
0.42%
Revenue per employee (TTM)
-$10,000
Management effectiveness
Return on assets (TTM)
-39.44%
Return on equity (TTM)
-56.52%
Valuation
Price to revenue (TTM)
-1,675.532
Price to book
4.37
Price to tangible book (TTM)
4.37
Price to free cash flow (TTM)
-7.21
Free cash flow yield (TTM)
-13.87%
Free cash flow per share (TTM)
-1.835
Growth
Revenue change (TTM)
-100.34%
Earnings per share change (TTM)
-53.58%
3-year revenue growth (CAGR)
24.45%
3-year earnings per share growth (CAGR)
-24.95%
AMLX News
AllArticlesVideos
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
Business Wire·6 days ago
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
Business Wire·4 weeks ago
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.5B as of December 12, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of December 12, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of December 12, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.33. This means that it has an inverse relation to market volatility.